Previous close | 51.91 |
Open | 51.79 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 51.79 - 51.79 |
52-week range | 29.10 - 55.50 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Insightful Analysis of Catalent Inc's Strengths, Weaknesses, Opportunities, and Threats
Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?